Journal of Antimicrobial Chemotherapy (2000) 45, 55
© 2000 The British Society for Antimicrobial Chemotherapy
Review of the in vitro activity of gemifloxacin against Gram-positive and Gram-negative anaerobic pathogens
R. M. Alden Research Laboratory, Santa Monica–UCLA Medical Center, Santa Monica, CA 90494 and the UCLA School of Medicine, Los Angeles, CA 90073, USA
Published reports on the in vitro activity of gemifloxacin mesylate (SB 265805), a new fluoronaphthyridone, against anaerobic pathogens are reviewed here. The studies used a variety of media, inocula and antimicrobial agents. Using a proposed breakpoint of 0.5 mg/L, these studies showed that gemifloxacin had generally higher potency against Gram-positive anaerobes (Clostridium perfringens, all Peptostreptococcus spp.) and fusobacteria (Fusobacterium nucleatum, Fusobacterium necrophorum) and moderate but variable potency against Gram-negative anaerobes. Bacteroides stercoris, Bacteroides tectum and many Bacteroides fragilis isolates were inhibited by concentrations of 
0.5 mg/L, while the other species of the B. fragilis group required higher concentrations for inhibition. Species variability was evident: Porphyromonas asaccharolytica, Porphyromonas canoris, Porphyromonas gingivalis, Porphyromonas macaccae, Prevotella heparinolytica and Prevotella intermedia were susceptible to 0.5 mg/L of gemifloxacin while most other Porphyromonas and Prevotella spp. were not. These data suggest that gemifloxacin may have a clinical role in the treatment of certain dental, head and neck and pleuropulmonary infections in which Gram-positive anaerobes, fusobacteria and some Prevotella and Porphyromonas spp. may predominate.
* Correspondence address. 2021 Santa Monica Boulevard, Suite 640 East, Santa Monica, CA 90404, USA. Tel: +1-310-315-1511; Fax: +1-310-315-3662; E-mail: ejcgmd{at}aol.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Stephan, H. A. Greife, A. Pridmore, and P. Silley Activity of Pradofloxacin against Porphyromonas and Prevotella spp. Implicated in Periodontal Disease in Dogs: Susceptibility Test Data from a European Multicenter Study Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2149 - 2155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Silley, B. Stephan, H. A. Greife, and A. Pridmore Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats J. Antimicrob. Chemother., November 1, 2007; 60(5): 999 - 1003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Pereyre, H. Renaudin, C. Bebear, and C. M. Bebear In Vitro Activities of the Newer Quinolones Garenoxacin, Gatifloxacin, and Gemifloxacin against Human Mycoplasmas Antimicrob. Agents Chemother., August 1, 2004; 48(8): 3165 - 3168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kraiczy, J. Weigand, T. A. Wichelhaus, P. Heisig, H. Backes, V. Schafer, G. Acker, V. Brade, and K.-P. Hunfeld In Vitro Activities of Fluoroquinolones against the Spirochete Borrelia burgdorferi Antimicrob. Agents Chemother., September 1, 2001; 45(9): 2486 - 2494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kleinkauf, G. Ackermann, R. Schaumann, and A. C. Rodloff Comparative In Vitro Activities of Gemifloxacin, Other Quinolones, and Nonquinolone Antimicrobials against Obligately Anaerobic Bacteria Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1896 - 1899. [Abstract] [Full Text]
|
|